Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
Switch from perforin-expressing to perforin-deficient CD8+ T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo
Immunology, 08/19/09
Meiraz A et al. – The results show that as the immune response progresses in vivo, targeted cellular suicide mainly prunes high perforin–expressing CD8+ cells, resulting in the gradual switch in effector CTL, from mostly perforin–based to largely Fas/FasL–based killers. Hence, two kinds of CD8+ CTL have two killing strategies.
Related Articles
Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?
Arthritis Research & Therapy, 10/14/09
Relevance Score: 81%
Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1
Journal of Leukocyte Biology, 11/09/09
Relevance Score: 80%
Zeta chain expression in T and NK cells in peripheral blood of children with nephrotic syndrome
Pediatric Nephrology, 10/28/09
Relevance Score: 79%
Role of CD8+ T-cell immunity in influenza infection: potential use in future vaccine development
Expert Review of Respiratory Medicine, 10/14/09
Relevance Score: 79%
Measurement of cytotoxic T lymphocyte activity of human cytomegalovirus seropositive individuals by a highly sensitive coupled luminescent method
Medical Microbiology and Immunology, 10/13/09
Relevance Score: 79%
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Clinical Cancer Research, 12/01/09
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Clinical Cancer Research, 12/01/09
Sponsor
Article Search
Sponsor


See Latest Articles


